ADVI Analysis: MACPAC Meeting January 2023

Pharmaceuticals and Biotech Federal And State Policy Pharmaceuticals and Biotech Reimbursement

January 27, 2023

Medicaid and CHIP Payment and Access Commission (MACPAC) Meeting: January 2023 Executive Summary

The MACPAC held a meeting on January 26-27, 2023 (link). The following relevant topics were discussed.

  • Medicaid coverage based on Medicare National Coverage Determination (NCD): Review of recommendations and draft chapter for March report
  • Discussion of Potential Responses to HHS Rulemaking
  • State update on unwinding the Public Health Emergency (PHE)

ADVI Angle

The following are key takeaways from the January meeting.

  • Medicaid coverage based on Medicare National Coverage Determination (NCD): Review of recommendations and draft chapter for March report
    • MACPAC Staff presented a draft chapter and recommendation to allow states to follow a Medicare NCD or CED requirements.
    • Commissioners voted to advance the following recommendations to be included in the March 2023 Report to Congress:
      • Congress should amend § 1927(d)(1)(B) of the Social Security Act to allow states to exclude or otherwise restrict coverage of a covered outpatient drug based on coverage with evidence development requirements implemented under a Medicare national coverage determination.
      • Congress should amend Section 1903(m)(2)(A)(xiii) to require the managed care contract conform to the state’s policy with respect to any exclusion or restriction of coverage of a covered outpatient drug based on coverage with evidence development requirements implemented under a Medicare national coverage determination.
    • Discussion of Potential Responses to HHS Rulemaking
      • MACPAC Staff presented on comment opportunities for the Commission in the following proposed rules: Notice of Benefit and Payment Parameters for 2024, Contract Year 2024 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs, and the Confidentiality of Substance Use Disorder (SUD) Patient Records.
    • State update on unwinding the Public Health Emergency (PHE)
      • MACPAC Staff along with state panelists from CO, OK, and NV, provided an update on how states are planning for the unwinding of the continuous coverage requirement considering the passage of the 2023 Consolidated Appropriations Act (CAA, P.L. 117-328).

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Precision Medicine

CMS Proposes RAPID Coverage Pathway for Breakthrough Devices

IVDs remain outside scope, while FDA-CMS Parallel Review remains available. KEY TAKEAWAY RAPID could materially shorten the gap between Food …

August 21, 2026

Why Clinical Laboratories Should Consider Weighing In on CMS and CDC’s New CLIA Request for Information

An opportunity for laboratories to help shape the future of CLIA regulation On July 16, 2026, the Centers for Medicare …

July 27, 2026

Precision Medicine

The MolDX Technical Assessment: How to Move Your Test from “Not Successful” to Medicare Coverage Success

In the laboratory space, the MolDX Technical Assessment (TA) is often the moment where the gap between “a great test” …

April 9, 2026

Precision Medicine

CRUSH and Genetic and Molecular Laboratories: A Potential Shift in Medicare Oversight

Genetic, molecular, and reference laboratories are closely watching a new Medicare concept known as CRUSH- short for Comprehensive Regulations to …

March 17, 2026

Oncology/biologics Precision Medicine

March Is Colorectal Cancer Awareness Month: Why CMS’s Proposed NCD 210.3 Update Could Accelerate Patient‑Centered Screening Access

Colorectal cancer (CRC) screening saves lives, but only when patients are able to access care in a way that meets …

March 17, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Precision Medicine

A New Era for Cancer Detection Begins with the Sewell MCED Law

We are seeing a long‑anticipated and important policy inflection point.  By now you might have heard that Congress passed the …

February 11, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.